These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 29516230)

  • 1. The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions.
    Ofstad AP; Atar D; Gullestad L; Langslet G; Johansen OE
    Heart Fail Rev; 2018 May; 23(3):303-323. PubMed ID: 29516230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology.
    Seferović PM; Petrie MC; Filippatos GS; Anker SD; Rosano G; Bauersachs J; Paulus WJ; Komajda M; Cosentino F; de Boer RA; Farmakis D; Doehner W; Lambrinou E; Lopatin Y; Piepoli MF; Theodorakis MJ; Wiggers H; Lekakis J; Mebazaa A; Mamas MA; Tschöpe C; Hoes AW; Seferović JP; Logue J; McDonagh T; Riley JP; Milinković I; Polovina M; van Veldhuisen DJ; Lainscak M; Maggioni AP; Ruschitzka F; McMurray JJV
    Eur J Heart Fail; 2018 May; 20(5):853-872. PubMed ID: 29520964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms.
    Savarese G; Butler J; Lund LH; Bhatt DL; Anker SD
    Cardiovasc Res; 2022 Jul; 118(10):2231-2252. PubMed ID: 34390570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
    Seferović PM; Coats AJS; Ponikowski P; Filippatos G; Huelsmann M; Jhund PS; Polovina MM; Komajda M; Seferović J; Sari I; Cosentino F; Ambrosio G; Metra M; Piepoli M; Chioncel O; Lund LH; Thum T; De Boer RA; Mullens W; Lopatin Y; Volterrani M; Hill L; Bauersachs J; Lyon A; Petrie MC; Anker S; Rosano GMC
    Eur J Heart Fail; 2020 Feb; 22(2):196-213. PubMed ID: 31816162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Singh AK; Singh R
    Diabetes Metab Syndr; 2021; 15(1):351-359. PubMed ID: 33503584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Important Considerations for the Treatment of Patients with Diabetes Mellitus and Heart Failure from a Diabetologist's Perspective: Lessons Learned from Cardiovascular Outcome Trials.
    Koliaki C; Katsilambros N
    Int J Environ Res Public Health; 2019 Dec; 17(1):. PubMed ID: 31878281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.
    Mentz RJ; Brunton SA; Rangaswami J
    Cardiovasc Diabetol; 2023 Nov; 22(1):316. PubMed ID: 37974185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits.
    Hupfeld C; Mudaliar S
    Diabetes Obes Metab; 2019 Aug; 21(8):1780-1789. PubMed ID: 30957945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Handelsman Y
    Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes.
    Standl E; Schnell O; McGuire DK
    Circ Res; 2016 May; 118(11):1830-43. PubMed ID: 27230644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heart Failure With Type 2 Diabetes Mellitus: Association Between Antihyperglycemic Agents, Glycemic Control, and Ejection Fraction.
    Lin SN; Phang KK; Toh SH; Chee KH; Zaman Huri H
    Front Endocrinol (Lausanne); 2020; 11():448. PubMed ID: 32754118
    [No Abstract]   [Full Text] [Related]  

  • 14. Heart Failure in Type 2 Diabetes Mellitus.
    Kenny HC; Abel ED
    Circ Res; 2019 Jan; 124(1):121-141. PubMed ID: 30605420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin treatment in heart failure with preserved ejection fraction: a systematic review and meta-regression analysis.
    Halabi A; Sen J; Huynh Q; Marwick TH
    Cardiovasc Diabetol; 2020 Aug; 19(1):124. PubMed ID: 32758236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus.
    Asleh R; Sheikh-Ahmad M; Briasoulis A; Kushwaha SS
    Heart Fail Rev; 2018 May; 23(3):445-459. PubMed ID: 29270818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heart failure and diabetes: Clinical significance and epidemiology of this two-way association.
    Jerkins T; McGill JB; Bell DSH
    Diabetes Obes Metab; 2023 Jul; 25 Suppl 3():3-14. PubMed ID: 36949650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure.
    Galli M; D'Amario D; Sofia C; Vaccarella M; Crea F; Aspromonte N
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1273-1285. PubMed ID: 30472914
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
    Kato ET; Silverman MG; Mosenzon O; Zelniker TA; Cahn A; Furtado RHM; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Bonaca MP; Ruff CT; Desai AS; Goto S; Johansson PA; Gause-Nilsson I; Johanson P; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
    Circulation; 2019 May; 139(22):2528-2536. PubMed ID: 30882238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes.
    Katsiki N; Kazakos K; Triposkiadis F
    Expert Opin Pharmacother; 2022 Dec; 23(17):1957-1974. PubMed ID: 36322877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.